Management of Cerebrovascular Accident Due to Apical Thrombus

Initial Assessment and Management

The American Heart Association recommends performing rapid evaluation of airway, breathing, and circulation to ensure basic physiological stability 1
The American Heart Association suggests providing supplemental oxygen to maintain oxygen saturation ≥94% 1
The European Heart Society recommends performing immediate neuroimaging (preferably CT) to differentiate between ischemic and hemorrhagic stroke 2
The National Institutes of Health recommends assessing stroke severity using a standardized scale such as the National Institutes of Health Stroke Scale (NIHSS) 1
The European Society of Cardiology recommends that for patients with suspected left ventricular thrombus, transthoracic echocardiography should be performed to confirm the diagnosis 3, 4

The American Heart Association recommends that for eligible patients presenting within the time window (typically 3-4.5 hours from symptom onset), intravenous thrombolysis with tissue plasminogen activator (tPA) should be considered 2
The European Heart Society suggests that current evidence indicates the small increased risk of intracranial hemorrhage in patients on antiplatelet therapy is outweighed by the larger benefit from thrombolysis 5
The European Heart Society recommends that after excluding intracranial hemorrhage, initiate anticoagulation therapy promptly to prevent further thromboembolic events 5

The European Society of Cardiology recommends that for patients with left ventricular thrombus, anticoagulation with warfarin (INR 2.0-3.0) should be administered for up to 6 months 3, 6
The American College of Chest Physicians recommends that for patients who have undergone stent placement and have apical thrombus, triple therapy (warfarin [INR 2.0-3.0], low-dose aspirin, clopidogrel 75 mg daily) for 1 month, followed by warfarin and single antiplatelet therapy for the second and third month 6
The European Society of Cardiology recommends that anticoagulation therapy should be guided by repeated imaging to confirm thrombus resolution 3, 7

The European Heart Society recommends that for patients with persistent apical akinesia, even after thrombus resolution and LVEF improvement, continued anticoagulation may be warranted due to the risk of thrombus recurrence 3, 7
The European Society of Cardiology suggests that the absence of bleeding events and lack of comorbidities or frailty features support sustained anticoagulation in patients with persistent wall motion abnormalities 7

The European Society of Cardiology recommends regular echocardiographic assessment to monitor thrombus resolution 3, 7
The European Heart Society suggests that anticoagulation can be discontinued after confirmation of thrombus resolution, but patients with persistent wall motion abnormalities should be monitored closely for recurrence 7
The European Society of Cardiology recommends that in cases of recurrent thrombus formation, long-term anticoagulation should be considered 7

The European Heart Society warns that delaying anticoagulation in patients with confirmed left ventricular thrombus increases the risk of embolic events 5
The European Society of Cardiology cautions that premature discontinuation of anticoagulation before thrombus resolution or in patients with persistent wall motion abnormalities may lead to thrombus recurrence 7
The European Heart Society advises against failure to recognize the importance of repeated imaging to guide the duration of anticoagulation therapy 3, 7
The American Heart Association recommends against administering aspirin or other antithrombotic agents before brain imaging rules out hemorrhagic stroke 1